Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.58 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.47 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16696294 | 0.85 | L3MBTL1 (0.66) | PIK3CAPIK3CBMAPK1HSD17B10L3MBTL1 | |
| SCHEMBL13059941 | 0.82 | MAPK1 (0.76) | PIK3CAPIK3CBMAPK1HSD17B10L3MBTL1 | |
| SCHEMBL21054811 | 0.79 | PIK3CA (0.58) | PIK3CAPIK3CBMAPK1HSD17B10L3MBTL1 | |
| SCHEMBL1434868 | 0.78 | PIK3CA (0.70) | PIK3CAPIK3CBMAPK1HSD17B10SMN1; SMN2 | |
| SCHEMBL4433854 | 0.78 | MTOR (0.47) | — | |
| SCHEMBL4433861 | 0.78 | MTOR (0.47) | — | |
| SCHEMBL4439640 | 0.78 | ADORA2A (0.44) | PIK3CAPIK3CBMAPK1HSD17B10L3MBTL1 | |
| SCHEMBL189594 | 0.77 | PIK3CA (0.72) | PIK3CAPIK3CBSMN1; SMN2PIKFYVEPIK3R1 | |
| SCHEMBL4446531 | 0.77 | SMN1; SMN2 (0.51) | PIK3CAPIK3CBMAPK1HSD17B10SMN1; SMN2 | |
| SCHEMBL11307534 | 0.77 | HTR2C (0.70) | PIK3CAPIK3CBHSD17B10L3MBTL1PIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENETECH, INC | 2010-11-18 | — | — | US | claimed |
| EP-2214675-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | Genentech, Inc. (US) | 2010-08-11 | — | — | EP | claimed |
| WO-2009055730-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH, INC. (US) | 2009-04-30 | — | — | WO | claimed |
| US-11603372-B2 | Compounds and therapeutic uses thereof | VIOGEN BIOSCIENCES, LLC (US) | 2023-03-14 | — | — | US | disclosed |
| US-20210122752-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VIOGEN BIOSCIENCES, LLC | 2021-04-29 | — | — | US | disclosed |
| US-20210122752-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | VIOGEN BIOSCIENCES, LLC | 2021-04-29 | — | — | US | disclosed |
| WO-2019113523-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | BAJJI ASHOK (US) | 2019-06-13 | — | — | WO | disclosed |
| WO-2019113523-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | BAJJI ASHOK (US) | 2019-06-13 | — | — | WO | disclosed |
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| EP-2046799-B1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2046799-B1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH INC (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2008073785-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008070740-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIRAMED LIMITED (GB) | 2008-03-27 | — | — | US | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| WO-2007127183-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127183-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GENENTECH, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007127175-A2 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CB 3/4885MAPK1 251/4885 |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIK3CA, PI4KB, PI4KA | PIK3CA 1/4885PIK3CB 4/4885MAPK1 91/4885 |
| US-20080076758-A1 | 1S,4S)-2-((2-(1H-indazol-4-yl)-4- morpholinothieno[3,2-d]pyrirnidin-6- yl)methyl)-5-methylsulfonyl-2,5- diaza-bicyclo[2.2.1]heptane; 2-(6-fluoropyridin-3-yl)-6-((4- methylsulfonylpiperazin-1-yl)methyl)-4- morpholinothieno[3,2-d]pyrimidine; treats cancer mediated by pik3 kinase; enzyme inhibitors | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3CB 3/4885MAPK1 194/4885 |
| US-11603372-B2 | Compounds and therapeutic uses thereof | IL15, IL17A, IL2 | PIK3CA 1586/4885PIK3CB 1423/4885MAPK1 3670/4885 |
| US-20210122752-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | IL15, IL17A, IL2 | PIK3CA 1586/4885PIK3CB 1423/4885MAPK1 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.